ARIAD Announces Completion of Public Offering
CAMBRIDGE, Mass. -- January 29, 2013
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of
its previously announced public offering of 15,307,000 shares of common stock
at a public offering price of $19.60 per share. In addition, the underwriters
have exercised an option to purchase an additional 1,182,893 shares at $19.60
per share to cover over-allotments. The total gross proceeds from the offering
are approximately $323 million. Net proceeds to ARIAD are approximately $310
million after deducting underwriting discounts and commissions and estimated
J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company,
Inc. acted as joint book-running managers and underwriters for the offering.
BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS
Investment Bank acted as co-managers for the offering.
A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (the “SEC”) and is effective. A final prospectus
supplement relating to the offering has been filed with the SEC. Copies of the
final prospectus supplement and accompanying prospectus may be obtained from
the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204),
the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806),
or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by
telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the
lives of cancer patients. For more information about ARIAD, visit the
company’s website at www.ariad.com.
ARIAD Pharmaceuticals, Inc.
Kendra Adams, 617-503-7028
Liza Heapes, 617-621-2315
Press spacebar to pause and continue. Press esc to stop.